COVID-19 inactivated vaccine (Sinopharm Holdings), developed by Beijing Institute of Biological Products of China Pharmaceutical Group, officially passed the WHO emergency use certification, becoming the sixth COVID-19 vaccine that passed the WHO safety, effectiveness and quality verification.
Group profile:
China Pharmaceutical Group Co., Ltd., namely China Pharmaceutical Group, is the largest pharmaceutical and health industry group with the most complete industrial chain and the strongest comprehensive strength in China directly managed by the State-owned Assets Supervision and Administration Commission of the State Council.
It focuses on distribution, retail, research and development and production of health-related products, such as preventive treatment and diagnostic care. It has more than 65,438+0,500 subsidiaries, and six listed companies, including Sinopharm Holdings, Sinopharm Shares, Sinopharm Consistent, Tiantan Bio, Hyundai Pharmaceutical and China Traditional Chinese Medicine.